Company intelligence / Profile preview

Pharma15

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Pharma15 is an early-stage biotech developing next-generation therapeutic radiopharmaceuticals and antibody-based radio‑immuno theranostic platforms for prostate cancer, aiming to overcome resistance to current PSMA-targeted therapies; its programs are in early preclinical development with no clinical data yet reported.[1][3]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibodyRadiopharmaceutical
Industry: Biotech

Partnerships

Radiopharm Theranostics (acquisition and development partnership)[1][7]

Beyond the preview

Go deeper on Pharma15.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharma15.

Explore the full profile